|Bid||76.54 x 1100|
|Ask||76.60 x 1400|
|Day's range||75.52 - 76.85|
|52-week range||60.89 - 85.97|
|Beta (5Y monthly)||0.71|
|PE ratio (TTM)||19.59|
|Earnings date||28 Jul 2020 - 03 Aug 2020|
|Forward dividend & yield||2.72 (3.64%)|
|Ex-dividend date||11 Jun 2020|
|1y target est||80.67|
A retrospective analysis said the still-experimental antiviral infusion significantly reduces COVID-19 patients' risk of death.
(Bloomberg) -- A coronavirus vaccine may be two years away, if one is ever found, and low levels of infection may become a part of life, Australia’s deputy chief medical officer warned.U.S. military facilities in Okinawa have found a total of at least 50 coronavirus cases, NHK said. New infections in Tokyo exceeded 200 for a third day, though fell short of Friday’s record, Kyodo reported. Masked fans returned to baseball in Japan, making the country among the first to restart major sport with spectators.In the U.S., Texas hospitalizations topped 10,000 for the first time and California suffered its second-highest day of deaths. Florida’s biggest county had a record number of patients in intensive care.Key Developments:Global Tracker: Cases top 12.5 million; deaths surpass 560,000Wuhan shows the world how economies may recover‘Back to the nightmare’ as virus shuts Hong Kong schoolsTesting bottlenecks are hindering U.S. statesJapan urges urbanites to tour country, sparks virus fearBillionaire’s empire unexpectedly thrives in BrazilMasked fans return to baseball in JapanSubscribe to a daily update on the virus from Bloomberg’s Prognosis team here. Click VRUS on the terminal for news and data on the coronavirus.U.S. Bases in Okinawa Find More Than 50 Cases: NHK (5:15 p.m. HK)U.S. military facilities in Okinawa, including Marine Corps Air Station Futenma and Camp Hansen, have found a total of at least 50 coronavirus cases, NHK reported Saturday, citing unidentified people. NHK cited Okinawa Governor Denny Tamaki as saying many new virus cases have been confirmed at the bases.Virus Spreads Fastest in Cooler Temperatures: Telegraph (5 p.m. HK)Coronavirus spreads fastest at 4 degrees Celsius (39 Fahrenheit), U.K. government scientists said, adding to concern about a winter resurgence, the Telegraph reported. The Scientific Advisory Group for Emergencies is thought to be focusing on the precise temperature as Melbourne, which is currently in its coldest month, went into a six-week lockdown due to a spike in cases.Russian Case Increase in Line With Past Week (3:37 p.m. HK)Russia reported 6,611 new confirmed coronavirus infections in the past day, in line with increases in the past week, raising the total to 720,547, according to data from the Russian government’s virus response center. Almost 27% of new cases were asymptomatic. In the past day 188 people died of the disease, bringing total death toll to 11,205.Slovenia confirmed 34 new coronavirus infections on Friday, the most since mid-April, bringing the total number of infected to 1,793. The number of fatalities remains at 111.German Infection Rate Rises Slightly (2:28 p.m. HK)Germany’s coronavirus cases rose by 331 while the death rate held steady, according to data from Johns Hopkins University. Deaths increased by 6 to 9,063, a smaller increase than most days since the beginning of March.The reproduction factor -- or R value -- rose slightly to 0.80, according to the latest estimate by the Robert Koch Institute, Germany’s health body. That’s under the key threshold of 1.0, seen as crucial to preventing a second wave of infections.Tokyo Finds 206 New Cases: Kyodo (2:02 p.m. HK)Tokyo confirmed 206 new cases of coronavirus, Kyodo reported Saturday, citing unidentified people. The number of new cases exceeded 200 for the third straight day, but fell short of Friday’s daily record of 243.Hong Kong Adds at Least 20 Cases: SCMP (1:53 p.m. HK)Hong Kong confirmed at least 20 new coronavirus cases on Saturday, the South China Morning Post reported, citing a medical source. It’s not yet known how many of Saturday’s cases were locally transmitted, the SCMP said. On Thursday, the city recorded 34 locally transmitted infections, the most in a single day since the pandemic began.In response, the government reintroduced social restrictions that cap restaurant capacity at 60% and limit eight people to a table.Australia Warns of Two-Year Vaccine Wait (1:21 p.m. HK)Australia’s Deputy Chief Medical Officer Nick Coatsworth said a vaccine may not be available for between 18 and 24 months and the country must be able to keep the virus under control at low levels. “We need to prepare for a world without a vaccine,” he said at a media conference Saturday.Mask-wearing will be critical to reopening Australia’s second-most populous state as it seeks to curb a second wave of infections, Victoria Premier Daniel Andrews said earlier.Two million masks will be ordered and distributed to “priority groups,” he said Saturday. The state recorded 216 new cases and one death in the past 24 hours, and he urged Victorians to stay home this weekend as much as possible.Emirates to Cut 9,000 Jobs, BBC Reports (11:08 a.m. HK)Emirates Airlines plans to cut 9,000 jobs because of the coronavirus outbreak, BBC reported, citing airline President Tim Clark.The company had 60,000 employees before the pandemic, the BBC said. The airline plans to increase job cuts to as much as 15% of its workforce, having already reduced employee numbers by 10%, Clark told the news service.South Korea New Cases Fall (9:29 a.m. HK)South Korea reported 35 more cases in 24 hours, raising the total tally to 13,373. There no additional deaths, leaving the total at 288, the Korea Centers for Disease Control & Prevention said.The country reported 45 new cases of infection on July 10 and one additional death.Japan’s Contact-Tracing App Fails (8:49 a.m. HK)Japan’s health ministry suspended the registration of positive cases on its contact-tracing smartphone app Cocoa as it worked to fix an error that left some people unable to enter their information.The ministry aims to get the feature running again next week, according to a statement. The ministry encouraged users to keep using the app, which had 6.5 million downloads across iOS and Android phones as of Friday evening.Texas Hits Milestone (5:35 p.m. NY)More than 10,000 people were hospitalized with Covid-19 in Texas Friday, the first time the state has reached that benchmark. Cases there jumped by 9,765, an increase of 4.2% compared with the seven-day average of 3.9%. The state has added close to 10,000 cases for each of the last four days, and deaths have begun to spike in tandem, with another 98 fatalities exceeding the seven-day average.Governor Greg Abbott stepped up efforts to encourage people to wear masks, making the rounds of local television stations to warn that deaths are likely to rise in coming days.California to Release Prisoners (4:30 p.m. NY)California plans to release about 7% of its prison population, roughly 8,000 non-violent offenders, to relieve pressure on a chronically overcrowded correctional system that’s now struggling with a spike in coronavirus cases.The move will enable prisons to maximize available space to implement physical distancing, isolation and quarantine efforts, the California Department of Corrections and Rehabilitation said in a statement. It estimated that about 8,000 currently incarcerated people could be eligible for release by the end of August.U.S. Cases Rise 1.9% (3:55 p.m. NY)U.S. cases rose by 59,782 from a day earlier to 3.14 million, according to data collected by Johns Hopkins University and Bloomberg News. The 1.9% jump matched the average daily increase over the past week. Deaths rose 0.7% to 133,677.California Has Second-Deadliest Day (2:21 p.m. NY)California reported 140 new virus deaths, second only to the 149 reported Thursday as the most yet for the pandemic. The 14-day average is 75, according to state health data.Total confirmed cases rose by 7,798, or 2.6%, pushing California’s total infections to 304,297. While the gain was less than the 3% average over the past seven days, the state’s outbreak has been accelerating: Infections have exceeded 300,000 just two weeks after crossing the 200,000 milestone.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Gilead Sciences' (NASDAQ: GILD) remdesivir cut the risk of death by 62% in severe COVID-19 patients. While the results, which were presented at the Virtual COVID-19 Conference as part of the 23rd International AIDS Conference, sound great, they come from a retrospective analysis comparing results from two different data sources. The remdesivir mortality rate comes from results of patients in Gilead's phase 3 SIMPLE-Severe clinical trial.
The global energy agency that rarely helps the positive case in oil has given a friendly boost to those long crude, just as the week comes to an end. Crude prices jumped more than 1% on Friday after the International Energy Agency bumped up its 2020 forecast for global oil demand, lifting a market that took its worst hammering in six weeks in the previous session. The IEA’s outlook on oil has typically been dour over the past few years, putting it at odds with the Saudi-dominated OPEC — or Organization of the Petroleum Exporting Countries — whose members are determined to keep crude prices supported under any condition.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
Remdesivir has been at the forefront of the global battle against COVID-19 after the intravenously administered medicine helped shorten hospital recovery times, according to data in April from a separate U.S. government trial. In the latest analysis, Gilead said it analyzed data from 312 patients treated in its late-stage study and a separate real-world retrospective cohort of 818 patients with similar characteristics and disease severity. Gilead's late-stage study evaluated the safety and efficacy of five-day and 10-day dosing durations of remdesivir in hospitalized patients.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data on remdesivir, an investigational antiviral for the treatment of COVID-19, adding to the available body of knowledge on treatment outcomes with remdesivir. The data are being presented at the Virtual COVID-19 Conference as part of the 23rd International AIDS Conference (AIDS 2020: Virtual) and include a comparative analysis of the Phase 3 SIMPLE-Severe trial and a real-world retrospective cohort of patients with severe COVID-19. In this analysis, remdesivir was associated with an improvement in clinical recovery and a 62 percent reduction in the risk of mortality compared with standard of care – an important finding that requires confirmation in prospective clinical trials.
Gilead (GILD) begins a phase I study to evaluate the safety, tolerability and pharmacokinetics of an investigational, inhaled solution of remdesivir for coronavirus.
The stock market has been resilient even in the face of ongoing uncertainty about the future of the economy, and Friday morning was no exception. Subscriptions could rise by 12.5 million or more during the quarter.
Gilead Sciences Inc <GILD.O> plans to make more of its drug remdesivir available for Germany and Europe from autumn and will decide how much each country gets based on the rate of infection, the drugmaker's Germany boss told a German magazine. Bettina Bauer, managing director of Gilead in Germany, told WirtschaftsWoche the U.S. drugmaker can increase its worldwide monthly production from currently 190,000 treatment cycles to 2 million treatment cycles in December.
The company said the trial, which will enroll about 60 healthy Americans aged between 18 and 45, will test the drug particularly in those cases where the disease has not progressed to require hospitalization. The drug is currently used intravenously and an inhaled formulation would be given through a nebulizer, which could potentially allow for easier administration outside hospitals. Remdesivir was granted emergency use authorization in the United States to treat severe cases of COVID-19 in patients who are hospitalized.
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data presented at the 23rd International AIDS Conference (AIDS 2020: Virtual) evaluating the impact of COVID-19 shelter-in-place orders (SIPOs) and PrEP utilization on HIV prevention strategies and associated risk behaviors. Findings presented included results from an online survey conducted by The American Academy of HIV Medicine (AAHIVM) to understand potential changes in behavior among pre-exposure prophylaxis (PrEP) users and prescribers in the United States during the height of COVID-19 SIPOs. There were 598 total respondents – 409 PrEP users and 189 PrEP prescribers. While most prescribers (90 percent) reported recommending no change in PrEP regimen, about one-third (33 percent) of PrEP users discontinued therapy voluntarily, mostly (85 percent) due to low perceived HIV risk associated with decreased sexual activity. Only 8 percent of those users who discontinued PrEP cited inability to access PrEP medications. Nearly all prescribers (95 percent) were able to successfully prescribe PrEP despite limitations caused by SIPOs.
Gilead Sciences (GILD) closed the most recent trading day at $76.42, moving -0.44% from the previous trading session.
Zacks.com featured highlights include: Bristol-Myers Squibb, Vale, Gilead Sciences, Kroger and Delek Logistics Partners
The past few months have seen pharmaceutical companies making every effort to develop a vaccine for the novel coronavirus.
Earnings yield is very important in comparing a stock with other stocks and with fixed income securities. A stock with higher earnings yield fetches better returns.
Gilead (GILD) gets conditional marketing authorization for Veklury (remdesivir) as a treatment for SARS-CoV-2 infection by the European Commission.
Mylan NV <MYL.O> said on Monday it would launch a generic version of Gilead Sciences Inc's <GILD.O> COVID-19 antiviral remdesivir in India at 4,800 rupees ($64.31), about 80% below the price tag on the drug for wealthy nations. California-based Gilead has signed licensing deals with several generic drugmakers in an effort to make remdesivir available in 127 developing countries. Last month, two Indian drugmakers, Cipla Ltd <CIPL.NS> and privately-held Hetero Labs Ltd, also launched generic versions of the treatment.
Contrarian value investors are always on the look-out for shares that the market has overlooked. In times of economic uncertainty - when stock prices become er...
At the end of April, shares of Gilead Sciences (NASDAQ: GILD) were hovering near their 52-week highs of $85.97. The stock has been falling since then, and it's now trading at just about $76. Year to date, the stock is still up 17%, and well above the 4% decline the S&P 500 has seen during the same period.
Remdesivir is an anti-viral drug that was developed for use against Ebola.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data demonstrating the safety and efficacy of the once-daily, single tablet regimen Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) in virologically suppressed adults ages 65 and older (n=140), including those with common comorbidities such as diabetes (22 percent), hypertension (55 percent), cardiovascular disease (24 percent), and dyslipidemia, which is an abnormal amount of lipids in the blood (59 percent). At 48 weeks, 92 percent of those who switched to Biktarvy maintained virologic suppression, achieving HIV RNA<50 copies/mL. Across the studies, Biktarvy was generally well tolerated. These data were evaluated as part of a pooled analysis of four international trials and will be presented during the 23rd International AIDS Conference (AIDS 2020: Virtual).
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from an ongoing Phase 1 study, which showed that a sustained-delivery subcutaneous formulation of the company’s investigational, novel inhibitor of HIV-1 capsid function, lenacapavir (GS-6207), sustained predicted therapeutic concentrations for at least six months following a single 900 mg dose. In the study, lenacapavir was generally well-tolerated, and no serious adverse events were reported. These data were presented at the 23rd International AIDS Conference (AIDS 2020: Virtual).